WallStSmart

Centene Corp (CNC)vsGilead Sciences Inc (GILD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Centene Corp generates 500% more annual revenue ($178.33B vs $29.74B). GILD leads profitability with a 31.0% profit margin vs -3.6%. CNC appears more attractively valued with a PEG of 1.25. GILD earns a higher WallStSmart Score of 68/100 (B-).

CNC

Buy

57

out of 100

Grade: C

Growth: 7.3Profit: 3.5Value: 7.0Quality: 6.5
Piotroski: 6/9Altman Z: 2.83

GILD

Strong Buy

68

out of 100

Grade: B-

Growth: 6.0Profit: 9.5Value: 7.3Quality: 6.5
Piotroski: 7/9Altman Z: 1.97
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CNCUndervalued (+85.0%)

Margin of Safety

+85.0%

Fair Value

$268.78

Current Price

$62.33

$206.45 discount

UndervaluedFair: $268.78Overvalued
GILDUndervalued (+43.9%)

Margin of Safety

+43.9%

Fair Value

$220.62

Current Price

$129.16

$91.46 discount

UndervaluedFair: $220.62Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CNC2 strengths · Avg: 9.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Free Cash FlowQuality
$3.40B8/10

Generating 3.4B in free cash flow

GILD6 strengths · Avg: 9.5/10
Return on EquityProfitability
39.2%10/10

Every $100 of equity generates 39 in profit

Profit MarginProfitability
31.0%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
39.3%10/10

Strong operational efficiency at 39.3%

EPS GrowthGrowth
54.8%10/10

Earnings expanding 54.8% YoY

Market CapQuality
$154.33B9/10

Large-cap with strong market position

P/E RatioValuation
16.9x8/10

Attractively priced relative to earnings

Areas to Watch

CNC2 concerns · Avg: 1.5/10
Return on EquityProfitability
-30.1%2/10

ROE of -30.1% — below average capital efficiency

Profit MarginProfitability
-3.6%1/10

Currently unprofitable

GILD3 concerns · Avg: 4.0/10
PEG RatioValuation
2.144/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.4%4/10

4.4% revenue growth

Altman Z-ScoreHealth
1.974/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CNC

The strongest argument for CNC centers on Price/Book, Free Cash Flow. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : GILD

The strongest argument for GILD centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.0% and operating margin at 39.3%.

Bear Case : CNC

The primary concerns for CNC are Return on Equity, Profit Margin.

Bear Case : GILD

The primary concerns for GILD are PEG Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

CNC profiles as a turnaround stock while GILD is a value play — different risk/reward profiles.

CNC carries more volatility with a beta of 1.09 — expect wider price swings.

CNC is growing revenue faster at 5.1% — sustainability is the question.

CNC generates stronger free cash flow (3.4B), providing more financial flexibility.

Bottom Line

GILD scores higher overall (68/100 vs 57/100), backed by strong 31.0% margins. CNC offers better value entry with a 85.0% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Centene Corp

HEALTHCARE · HEALTHCARE PLANS · USA

Centene Corporation is a large publicly traded company and a multi-line managed care enterprise that serves as a major intermediary for both government-sponsored and privately insured health care programs. It is a healthcare insurer that focuses on managed care for uninsured, underinsured, and low-income individuals.

Gilead Sciences Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Want to dig deeper into these stocks?